ArticleFrontiers in oncology2026
Cervical cancer with BRCA1 gene mutations: case reports and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mutations in breast cancer susceptibility genes (BRCA1 and BRCA2) are well-established risk factors for breast, ovarian, prostate, and pancreatic cancers. However, their occurrence in cervical cancer is rare, with a reported prevalence of less than 5%. To date, only a limited number of cervical cancer cases harboring BRCA mutations have been reported. Case presentation: We conducted a retrospective analysis of two cases of cervical cancer with germline BRCA1 mutations. Case 1: A 39-year-old woman presented with poorly differentiated squamous cell carcinoma of the cervix, classified as International Federation of Gynecology and Obstetrics (FIGO) stage IIA1. After radical hysterectomy, she received adjuvant chemoradiotherapy. Owing to a family history of cancer, genetic testing was performed, revealing a pathogenic germline BRCA1 mutation. One year later, she underwent prophylactic bilateral salpingo-oophorectomy. After 44 months of rigorous follow-up, no evidence of disease recurrence was observed. Case 2: A 26-year-old woman was diagnosed with poorly differentiated squamous cell carcinoma of the cervix, FIGO 2018 stage IVB. She received neoadjuvant chemotherapy followed by concurrent chemoradiotherapy and four additional cycles of combination chemotherapy. Whole-exome sequencing identified a germline BRCA1 mutation. Two years after the completion of initial treatment, imaging revealed metastatic involvement of lymph nodes in the left axilla. She subsequently received six cycles of palliative chemotherapy. At 50 months post-diagnosis, the patient remains alive under close clinical surveillance. Conclusion: In patients with cervical cancer, BRCA testing holds important clinical value, particularly for the management of those with a significant family history of malignancy or confirmed hereditary predisposition. Appropriate genetic counseling plays an essential role in guiding preventive strategies, facilitating early diagnosis, and supporting informed decision-making regarding potential prophylactic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.